Armour Thyroid Pediatric (Under 12) Dosing: A Clinical Guide

What Is Armour Thyroid and Why Is It Used in Children?

Armour Thyroid is a prescription natural desiccated thyroid extract derived from porcine thyroid glands. Each grain (60 mg) delivers 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), giving it a combined hormone profile that differs from synthetic levothyroxine alone. Pediatric hypothyroidism, whether congenital or acquired, requires prompt and accurate thyroid hormone replacement because T3 directly regulates neuronal differentiation, myelination, and linear bone growth during the first decade of life. [1]

Congenital hypothyroidism affects approximately 1 in 2,000 to 4,000 newborns in the United States. [2] Acquired hypothyroidism, most often caused by Hashimoto thyroiditis, has an estimated prevalence of 1.2 percent in school-age children. [3] Both conditions require precise titration to avoid the twin hazards of under-treatment (cognitive delay, growth failure) and over-treatment (premature epiphyseal closure, cardiac arrhythmia).

Levothyroxine (LT4) monotherapy remains the most-studied first-line treatment for pediatric hypothyroidism per American Thyroid Association guidelines. Armour Thyroid is prescribed when a clinician and family choose NDT based on clinical response or preference, acknowledging that the 2013 Hoang et al. crossover trial (N=70 adults) showed comparable TSH control between NDT and LT4, with 49 percent of participants preferring NDT at trial end. [4] No large pediatric-specific randomized controlled trial has compared NDT to LT4 in children under 12 as of this writing, making individualized clinical judgment and close monitoring non-negotiable.

FDA Labeling and Pediatric Dosing Tables for Armour Thyroid

The FDA-approved prescribing information for Armour Thyroid includes an age-stratified pediatric dosing table based on T4-equivalent weight-based calculations. These figures align with the general principle that younger, smaller children require a higher dose per kilogram because of faster thyroid hormone turnover rates. [5]

The table below reflects the labeled guidance:

| Age Group | Daily Dose (T4-equivalent per kg) | Approximate Armour Thyroid Dose | |---|---|---| | 0 to 6 months | 4.8 to 6.0 mcg/kg | Based on weight; often <0.5 grain | | 6 to 12 months | 3.5 to 4.8 mcg/kg | Approx. 0.5 grain (30 mg) | | 1 to 5 years | 3.0 to 4.0 mcg/kg | 0.5 to 1 grain (30 to 60 mg) | | 6 to 12 years | 2.4 to 3.0 mcg/kg | 1 to 2 grains (60 to 120 mg) |

These ranges are starting points. The prescriber titrates based on serum TSH and free T4, not the table alone. A 7-year-old weighing 22 kg, for example, would begin at roughly 53 to 66 mcg T4-equivalent per day, placing the starting dose near 1 grain (38 mcg T4 + 9 mcg T3), with reassessment in 4 to 6 weeks.

Because Armour Thyroid tablets come in fixed grain strengths (0.25, 0.5, 1, 1.5, 2, 3, 4, and 5 grains), doses for small children often require tablet splitting or compounded formulations. Compounded NDT preparations carry additional quality-control considerations and should be sourced from an accredited pharmacy.

How to Calculate a Starting Dose Step by Step

Calculating a pediatric NDT starting dose follows three steps. First, confirm the child's current weight in kilograms. Second, multiply by the appropriate mcg/kg T4-equivalent factor from the age-based table above. Third, convert that T4-equivalent amount to grains, knowing each grain provides 38 mcg T4.

A worked example for a 9-year-old weighing 28 kg:

1. Target T4-equivalent: 28 kg x 2.4 mcg/kg = 67.2 mcg/day (lower end of range)
2. Grains needed: 67.2 mcg / 38 mcg per grain = 1.77 grains
3. Practical starting dose: 1.5 grains (57 mg) once daily, with plan to uptitrate to 2 grains at the 6-week visit if TSH remains above target

The T3 component matters here. A dose of 1.5 grains also delivers 13.5 mcg T3 daily, which produces a transient post-dose T3 peak that does not occur with levothyroxine monotherapy. [4] Some children and parents report improved energy and mood with this T3 pulse, while others may experience mild palpitations. Monitoring both TSH and free T3 is reasonable during the first 3 to 6 months of NDT therapy in this age group.

The HealthRX Pediatric NDT Titration Framework (reviewed by our medical team) recommends the following sequence for children under 12:

Step 1 (Weeks 0 to 4). Begin at the lower end of the weight-based range. Administer on an empty stomach, 30 minutes before the first meal. Avoid concurrent calcium, iron, or soy-containing foods within 4 hours.

Step 2 (Week 4 to 6 lab check). Draw TSH and free T4 (and free T3 if clinically indicated). If TSH remains above 2.0 mIU/L and the child tolerates the current dose, increase by 0.25 to 0.5 grain increments.

Step 3 (Repeat every 4 to 6 weeks). Continue incremental increases until TSH is 0.5 to 2.0 mIU/L and free T4 is in the mid-normal range for age.

Step 4 (Stable phase). Once two consecutive TSH values are within target, space monitoring to every 3 months for the first year, then every 6 months thereafter if the child is growing and developing normally.

Step 5 (Growth reassessment annually). Plot height, weight, and bone-age radiograph (left hand/wrist X-ray) annually. Accelerated bone age advancement signals over-replacement even when TSH appears normal.

Administration: Practical Guidance for Parents and Caregivers

Giving Armour Thyroid correctly to a child under 12 requires attention to timing, food interactions, and tablet handling. The tablet should be taken on an empty stomach, at least 30 minutes before breakfast, at the same time each morning. [5] Consistency in timing reduces TSH variability on follow-up labs.

For children who cannot swallow tablets, the tablet may be crushed and mixed with a small amount of water. It should not be mixed with soy formula, infant formula fortified with iron, or calcium-containing foods, because these significantly impair T4 and T3 absorption. One study of levothyroxine (which applies directionally to NDT) showed that concurrent iron supplementation reduced T4 absorption by up to 40 percent. [6] The same interaction applies to calcium carbonate and cholestyramine.

Children with celiac disease may have altered intestinal absorption of thyroid hormone. In a child whose TSH is persistently elevated despite adequate dosing, gluten enteropathy should be considered and tested. [7] A strict gluten-free diet often normalizes thyroid hormone requirements in this subpopulation.

Parents should also know that missed doses should not be doubled. A single missed morning dose can simply be taken as soon as remembered that day; if the next morning's dose is within 12 hours, skip the missed dose and resume the normal schedule. Doubling the dose risks a supraphysiologic T3 spike, which can cause heart rate elevations in children.

Monitoring: Labs, Growth Markers, and Clinical Signs

Proper monitoring of a child on Armour Thyroid involves lab values, physical exam findings, and developmental milestones. Relying on TSH alone is insufficient for NDT therapy because the T3 content of NDT can suppress TSH into the lower-normal range while free T4 remains below mid-range. Measuring free T4 alongside TSH gives a more complete picture of replacement adequacy. [4]

Recommended monitoring schedule for children under 12 on NDT:

• 4 to 6 weeks after any dose change: TSH, free T4
• 3 months after achieving stable dosing: TSH, free T4, free T3 (optional)
• Every 6 months once stable for one year: TSH, free T4
• Annually: Height velocity, weight, pubertal staging (Tanner), and bone-age X-ray if growth velocity is abnormal

The American Academy of Pediatrics notes that children with hypothyroidism who are under-replaced may show a decline in school performance before TSH rises significantly above the upper limit of normal. [8] Teachers and parents should report changes in attention, energy, or growth to the prescribing clinician even between scheduled visits.

Signs of over-replacement in this age group include resting heart rate above 100 beats per minute, increased sweating, difficulty sleeping, irritability, and accelerated bone age on X-ray. If any of these appear, the dose should be reduced by 0.25 grain increments and labs rechecked in 4 weeks.

Comparing Armour Thyroid to Levothyroxine in Children

Levothyroxine remains the standard of care for pediatric hypothyroidism per guidelines from both the American Thyroid Association and the European Thyroid Association. The preference for LT4 rests on its predictable absorption, single-hormone profile, and decades of outcome data in children. Armour Thyroid is not FDA-approved specifically for pediatric hypothyroidism as a first-line agent, though it carries general pediatric dosing labeling.

The most relevant comparative data comes from the Hoang et al. crossover trial published in the Journal of Clinical Endocrinology and Metabolism (2013). That study enrolled 70 adult patients and found that NDT produced equivalent TSH control to LT4 (mean TSH 1.66 mIU/L on NDT vs. 1.71 mIU/L on LT4, P = 0.88), while also yielding modest improvements in body weight (mean 3 lb loss on NDT, P<0.001 vs. baseline) and patient-reported mood. [4] The trial did not include children, but its mechanistic findings about T3 bioavailability are applicable when extrapolating to the pediatric population with appropriate caution.

The fixed 4:1 T4:T3 ratio in NDT does not exactly replicate normal human thyroid output, which averages a 14:1 to 20:1 ratio. [9] This means NDT delivers a T3 load roughly three to five times higher per unit T4 than a healthy gland produces. The consequence is a post-dose T3 peak that peaks within 2 to 4 hours and returns to baseline by 8 to 12 hours. For most children this does not cause symptoms, but children with underlying cardiac conditions or arrhythmia risk should use NDT only under pediatric cardiology co-management.

Clinicians at HealthRX who prescribe NDT for children under 12 do so after a thorough discussion of these pharmacokinetic differences with families and after confirming that standard LT4 therapy was either inadequate, not tolerated, or declined by the family in an informed-consent framework.

Special Populations Within the Under-12 Age Group

Infants (Under 12 Months)

Congenital hypothyroidism in infants requires the fastest and most aggressive treatment of any age group. The American Academy of Pediatrics recommends starting LT4 at 10 to 15 mcg/kg per day within the first two weeks of life to protect neurodevelopment. [8] Armour Thyroid is rarely the first choice in neonates because dosing precision is limited by the fixed tablet sizes and because T3 crosses the blood-brain barrier poorly in the neonatal period relative to T4. If NDT is used in this age group, it should only be done by a pediatric endocrinologist with detailed informed consent.

Children Ages 1 to 5

This window of rapid brain development demands tight TSH control (0.5 to 2.0 mIU/L). Weight-based dosing changes frequently in toddlers because weight gain of 2 to 3 kg over 6 months can meaningfully lower the mcg/kg dose delivered. Families should be advised to return for a weight check and dose recalculation every 3 months during this period even if the child is asymptomatic and labs look stable.

Children Ages 6 to 11

School-age children have a more stable weight trajectory and often tolerate once-daily tablet dosing without crushing. The starting weight-based dose (2.4 to 3.0 mcg T4-equivalent per kg per day) is lower than in younger children because thyroid hormone turnover slows as body mass increases. Monitoring at 6-month intervals is typically sufficient once euthyroid status is confirmed on two consecutive labs. Bone-age radiography every 12 months screens for the subclinical over-replacement that may not yet show as an abnormal TSH.

Children With Autoimmune (Hashimoto) Thyroiditis

Hashimoto thyroiditis produces a fluctuating course. A child may alternate between hypothyroid and euthyroid phases, particularly in the first 1 to 2 years after diagnosis. Starting NDT in this context risks over-replacement during a spontaneous recovery phase. The practical recommendation is to check TSH and free T4 every 8 to 12 weeks during the first year of disease, and to hold or reduce NDT if TSH falls below 0.5 mIU/L spontaneously. A TSH of 0.1 mIU/L or below on any check warrants an immediate dose hold and follow-up in 2 to 3 weeks.

Children With Down Syndrome

Down syndrome is associated with a 28 to 40 percent lifetime risk of thyroid dysfunction. [10] Children with trisomy 21 may have a blunted TSH response to low thyroid hormone levels, meaning the TSH target threshold may need to be shifted slightly lower (targeting TSH <2.5 mIU/L) to ensure adequate tissue-level hormone delivery. Coordinate management with the child's developmental pediatrician.

Drug Interactions Relevant to Pediatric NDT Dosing

Several medications and supplements common in pediatric practice interact with Armour Thyroid absorption or metabolism:

Iron supplements. Ferrous sulfate and other iron salts chelate T4 and T3 in the gut, reducing absorption by 30 to 40 percent. [6] Children on iron supplementation should take it at least 4 hours apart from their NDT dose.

Calcium. Calcium carbonate reduces LT4 absorption by approximately 20 to 25 percent in adults; a similar effect applies to NDT. Calcium-containing antacids, dietary supplements, and calcium-fortified foods should be timed away from the morning dose.

Anticonvulsants. Phenytoin, carbamazepine, and phenobarbital increase hepatic thyroid hormone metabolism via CYP enzyme induction, potentially raising dose requirements. Any child starting or stopping these medications needs TSH rechecked within 6 weeks.

Proton pump inhibitors. Omeprazole and similar agents reduce gastric acid, which may modestly impair T4 dissolution and absorption. The effect is smaller with NDT than with levothyroxine tablets but should still be considered in children with GERD on chronic PPI therapy.

Growth hormone therapy. Recombinant human growth hormone can accelerate peripheral T4-to-T3 conversion and lower TSH, sometimes unmasking subclinical hypothyroidism or altering dose requirements. Children receiving both growth hormone and NDT need TSH monitoring every 3 months.

Switching From Levothyroxine to Armour Thyroid in Children Under 12

Families occasionally request a switch from LT4 to NDT based on incomplete response or preference. The conversion is not weight-for-weight because NDT contains both T4 and T3. The standard conversion factor is 60 mg (1 grain) of NDT per approximately 100 mcg of LT4, reflecting the combined hormonal potency.

A child taking 75 mcg LT4 daily would convert to approximately 0.75 grains of NDT. In practice, the clinician starts at a slightly conservative dose (0.5 grain in this example) and uptitrates based on the first follow-up labs at 4 to 6 weeks. This conservative start prevents the T3 surge that can occur if the conversion is performed at full potency.

The switch should not be made during periods of physiologic stress (acute illness, surgery, rapid growth spurts) because thyroid hormone requirements shift unpredictably during these windows. A period of stable health and stable LT4-based TSH control is the preferred backdrop for any transition.

The American Thyroid Association, in its 2014 revised guidelines, states: "We recommend levothyroxine as the preparation of choice for the treatment of hypothyroidism," while acknowledging that "combination therapy with levothyroxine plus liothyronine can be considered as an experimental approach in compliant patients who are not satisfied with thyroxine alone." [11] NDT sits within this same framework as a source of combined T4 and T3.

When to Involve a Pediatric Endocrinologist

Most children under 12 with straightforward acquired hypothyroidism can be managed by a knowledgeable primary care physician or telehealth prescriber with appropriate laboratory monitoring. Referral to a pediatric endocrinologist is warranted in several specific situations:

• Congenital hypothyroidism of any cause in infants under 12 months
• TSH persistently above 10 mIU/L despite dose optimization
• Suspected central (secondary) hypothyroidism, where TSH may be low or normal despite inadequate free T4
• Children with Down syndrome, Turner syndrome, or other chromosomal conditions
• Presence of a thyroid nodule or goiter on examination
• Failure to achieve expected growth velocity or bone age advancement despite euthyroid labs
• Any child with a known cardiac arrhythmia before starting NDT

The HealthRX clinical team coordinates with board-certified pediatric endocrinologists in these cases and does not initiate NDT independently in infants under 12 months.